我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
CNS Co Ltd is an information technology solutions company.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
招募中
100.0%
暂无批准数据
• Boston-based Newleos Therapeutics emerges with a $94 million Series A funding round led by Goldman Sachs, acquiring Roche's CNS drug portfolio with four clinical-stage candidates. • The company's pipeline targets significant unmet needs in mental health, including generalized anxiety disorder, substance use disorder, and cognitive impairment, affecting over 60 million U.S. adults. • Led by industry veterans from Longwood Fund, Newleos aims to advance multiple proof-of-concept clinical trials, with their most advanced candidate already completing Phase 1 studies for a rare neurodevelopmental disorder.
